A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent <i>In vivo</i> Therapeutic Activity

Abstract

ONCOFID-P significantly improved results obtained with conventional paclitaxel, in terms of in vivo tolerability and therapeutic efficacy; these data strongly support its development for locoregional treatment of ovarian cancer.